首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Randomized Double-Blinded Multicenter Placebo-Controlled Trial of Shenfu Injection for Treatment of Patients with Chronic Heart Failure during the Acute Phase of Symptom Aggravation (Yang and Qi Deficiency Syndrome)
【2h】

Randomized Double-Blinded Multicenter Placebo-Controlled Trial of Shenfu Injection for Treatment of Patients with Chronic Heart Failure during the Acute Phase of Symptom Aggravation (Yang and Qi Deficiency Syndrome)

机译:参附注射液治疗症状性急性加重(阳气虚证)急性心力衰竭患者的随机双盲多中心安慰剂对照试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background Shenfu injection (SFI) has shown a remarkable therapeutic effect in patients with chronic heart failure (CHF) during the acute phase of symptom aggravation since it became commercially available in 1987. However, the therapeutic effect of SFI has not been validated in a standard clinical study. As a pilot clinical trial, this study aimed to evaluate the safety and efficacy of SFI for treatment of CHF patients during the acute phase.
机译:自从1987年市售以来,神甫注射液(SFI)在症状加重的急性期对慢性心力衰竭(CHF)患者显示出显着的治疗效果。但是,SFI的治疗效果尚未在标准中得到验证临床研究。作为一项试验性临床试验,本研究旨在评估SFI在急性期治疗CHF患者的安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号